LITTLE FALLS, N.J., Nov. 7, 2012 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today the appointment of Jorgen B. Hansen as its Executive Vice President and Chief Operating Officer. Mr. Hansen will join Cantel on November 15 and will be responsible for the operations of all Cantel subsidiaries.
Mr. Hansen has been in global leadership positions with increasing responsibility within the healthcare and medical devices industry for over fifteen years. Most recently, he was Senior Vice President, Global Marketing, Business Development, Science and Innovation for ConvaTec Corp. Prior to that, he held leadership roles in Asia and Europe ranging from General Manager, Division head and Senior Vice President of Global Operations for Coloplast A/S. Mr. Hansen received his BS Degree in Mechanical Engineering from Copenhagen Technical University, and an International Commerce degree from the Copenhagen Business School in Denmark.
Mr. Andrew Krakauer, President and CEO of Cantel Medical Corp said, “With his extensive background in healthcare and experience in sales and marketing, manufacturing, business development, new product development, acquisitions and international business, Jorgen is the ideal person to fill the newly created and challenging position of Chief Operating Officer. He will play a major role in the planning and implementation of strategic growth plans for the Company.”
About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.
